Contract
Clinical Rater
Brooklyn Health
11-50 employees
AI-driven eCOA platform for CNS trials
No salary listed
Remote in USA
Remote
 Biology & Biotech (1) |
|---|
Get referred to Brooklyn Health
See people who can refer or advise you
- At least 5 years of experience as a Clinical Rater, Central Rater, or Secondary Reviewer on central nervous system clinical trials, such as Psychiatry or Neurology.
- Meticulous attention to detail with a strong background in clinical data evaluation, quality control frameworks, or trial quality assurance workflows.
- Demonstrated ability to interpret rater performance data, guide clinical decision-making, and manage site-facing interventions constructively.
- Perform manual, independent reviews of recorded clinical trial interviews and scale administrations to ensure scoring accuracy, interview quality, and protocol adherence.
- Maintain clear, reproducible documentation of review findings, scoring justifications, and site intervention plans aligned with protocol expectations.
- Participate in clinical decision-making regarding site performance, evaluate and provide interpretation for rater patterns, and directly oversee targeted site interventions and rater remediation; this responsibility applies to Senior Clinical Raters only.
Brooklyn Health builds Willis, an electronic Clinical Outcome Assessment (eCOA) platform for CNS clinical trials that uses AI and digital phenotyping to analyze clinical interviews by measuring spoken words, facial expressions, body language, and vocal tone to track symptoms over time. The platform is organized into OpenWillis (open-source phenotyping methods), WillisPipeline (converts behavioral data into clinical measures), and WillisAPI (integration with other digital health tools). This setup helps pharma teams use validated, standardized measures instead of creating their own, enabling more objective trial data. The company aims to improve the accuracy of treatment evaluation in CNS trials and reduce trial failures by better separating drug effects from placebo.
Company Size
11-50
Company Stage
Seed
Total Funding
$6.5M
Headquarters
New York City, New York
Founded
2023
Get referred to Brooklyn Health
See people who can refer or advise you
Simplify's Take
What believers are saying
- May 2025 seed round from HealthX funded hiring and pharma deployments.
- Brooklyn Health launched Willis on brooklyn.health and OpenWillis wiki in 2025.
- Bristol Myers Squibb and Boehringer Ingelheim references suggest enterprise interest in 2025.
What critics are saying
- IQVIA's June 2026 CNS white paper commoditizes Brooklyn Health's endpoint-validation pitch.
- Medidata, Veeva, and Signant already own enterprise clinical trial workflows in 2026.
- Six-point-five million seed funding limits runway against slower pharma procurement cycles.
What makes Brooklyn Health unique
- Founded 2023, Brooklyn Health standardizes CNS interview scoring with Willis eCOA.
- OpenWillis open-source library builds trust and speeds validation across researchers and sponsors.
- Anzar Abbas combines Cambridge Cognition and AiCure biomarker expertise into one platform.
Help us improve and share your feedback! Did you find this helpful?
Growth & Insights and Company News
6 month growth
↑ 4%1 year growth
↓ -4%2 year growth
↓ -4%HealthX Ventures has invested in Brooklyn Health, which uses AI-powered tools to improve mental health measurement in CNS clinical trials. Their platform offers objective, scalable assessments, enhancing trial outcomes and reducing placebo effects. Led by Dr. Anzar Abbas, Brooklyn Health's technology is gaining traction with pharma companies, ensuring accurate patient selection and trial integrity. Their open-science approach fosters trust, aiming to bring more effective therapies to market.
Brooklyn Health, a neuroscience technology company secured $6.5M in seed funding to expand AI-powered precision for clinical trial endpoints.
Brooklyn Health has raised $6.5 million to enhance the reliability of mental health drug trials by standardizing the assessment of their effects. The company's technology aims to address the issue of unreliable effect measurements, which can lead to trial failures even when the drugs are effective. Brooklyn Health plans to share its code to further this initiative.